Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02167594
Recruitment Status : Completed
First Posted : June 19, 2014
Last Update Posted : September 2, 2016
Sponsor:
Information provided by (Responsible Party):
Avid Radiopharmaceuticals

Brief Summary:
This study will evaluate 18F-AV-1451 for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.

Condition or disease Intervention/treatment Phase
Progressive Supranuclear Palsy Corticobasal Degeneration Drug: 18F-AV-1451 Drug: florbetapir F18 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers"
Study Start Date : July 2014
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016


Arm Intervention/treatment
Experimental: PSP Subjects
Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at screening. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline and at 9 months.
Drug: 18F-AV-1451
Other Name: T807

Drug: florbetapir F18
Other Names:
  • Amyvid
  • 18F-AV-45

Experimental: CBD subjects
Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at screening. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline and at 9 months.
Drug: 18F-AV-1451
Other Name: T807

Drug: florbetapir F18
Other Names:
  • Amyvid
  • 18F-AV-45

Experimental: Healthy volunteers
Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of 18F-AV-1451 at baseline.
Drug: 18F-AV-1451
Other Name: T807




Primary Outcome Measures :
  1. 18F-AV-1451 imaging in PSP, CBD and Healthy Volunteers [ Time Frame: 75-105 minutes post injection ]
    Compare standard uptake value ratio (SUVR) by diagnostic group (PSP, CBD and healthy volunteers).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Cognitively Healthy Volunteers

  • Mini-mental state examination (MMSE) ≥ 28
  • No history of cognitive decline or parkinsonian motor disorder

CBD and PSP subjects

  • Able to walk 10 steps with minimal assistance
  • MMSE ≥ 14 and ≤ 30
  • Subject has a reliable study partner who agrees to accompany subject to visits and spends at least 5 hours per week with the subject

PSP subjects only

  • Meet National Institute of Neurological Disorders and Stroke - Society for Progressive Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria as modified for the Neuroprotection and Natural History Parkinson Plus Syndromes (NNIPPS) clinical trial

CBD subjects only

  • Meets 2013 consensus criteria for possible or probably corticobasal degeneration, corticobasal syndrome (CBS) subtype

Exclusion Criteria:

All subjects

  • Have evidence of structural abnormalities such as vascular disease, large strokes or severe white matter disease or other mass lesion on screening MRI
  • Claustrophobia
  • Current clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG (e.g. QTC>450 msec)
  • Have a history of risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome)
  • Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
  • Have received or participated in a trial with investigational medications in the past 30 days
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
  • Have a history of neuroleptic use for a prolonged period of time or within the past 6 months

PSP and CBD subjects

  • Have evidence of amyloid deposition
  • Meet National Institute on Aging-Alzheimer's Association criteria for probable Alzheimer's Disease
  • Have any other neurological condition other than CBS or PSP that could account for cognitive or motor deficits
  • Serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay
  • Have a high-rsk family history suggestive of TDP-43 pathology or known mutations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02167594


Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, California
UCSD Movement Disorder Clinic
La Jolla, California, United States, 92037
UCSF Neurosciences Clinical Research Unit
San Francisco, California, United States, 94158
United States, Connecticut
Molecular Neuroimaging
New Haven, Connecticut, United States, 06510
United States, Pennsylvania
Perelman School of Medicine
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Avid Radiopharmaceuticals

Layout table for additonal information
Responsible Party: Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier: NCT02167594     History of Changes
Other Study ID Numbers: 18F-AV-1451-A09
First Posted: June 19, 2014    Key Record Dates
Last Update Posted: September 2, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Supranuclear Palsy, Progressive
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Ophthalmoplegia
Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Neurodegenerative Diseases
Paralysis
Neurologic Manifestations
Eye Diseases
Signs and Symptoms